Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development	$ 5,088,621	$ 7,252,241
General and administrative	6,191,845	11,094,146
Depreciation	67,981	25,342
Loss from operations	11,348,447	18,371,729
Interest expense, net	48,006	29,686
Change in fair value of warrant liability (Note 14)	(22,072,322)
Warrant related expenses (Note 10)	10,225,846
Other financing expenses	2,870,226
Loss from operations before income tax benefit	(2,420,203)	(18,401,415)
Income tax benefit	(1,055,685)	(364,796)
Net loss	(1,364,518)	(18,036,619)
Accretion of Series A cumulative preferred dividends	(1,252,394)
Net loss attributable to common stockholders	$ (2,616,912)	$ (18,036,619)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (0.21)	$ (1.76)
Net loss per share of common stock, diluted (in dollars per share)	$ (1.94)	$ (1.76)
Weighted average shares outstanding, basic (in shares)	12,447,641	10,232,791
Weighted average shares outstanding, diluted (in shares)	12,755,316	10,232,791